Asset profile
NT-0796
Small molecule
Evidence outlook · results not reported
RESOLVE-1 (NCT07055516) · Obesity and Type 2 Diabetes
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
RESOLVE-1 (NCT07055516): The trial was randomized, triple-blind, placebo-controlled, and included 176 participants. Its primary outcomes included the surrogate biomarker hsCRP and change in body weight, but the primary comparison cannot be judged because results have not been posted.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 1 direct rival (same mechanism and indication), 3 same-class, 60 same-indication; 50 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| NT-0796: this drug | Phase 2 | Small molecule | NLRP3 inflammasome | ||
| VTX3232 | Phase 2 | Small molecule | NLRP3 inflammasome, NLRP3 | ||
| ABP-745 | Phase 2 | Small molecule | NLRP3 inflammasome | ||
| AZD4144 | Phase 2 | Small molecule | NLRP3 inflammasome | ||
| Selnoflast | Phase 2 | Small molecule | NLRP3 inflammasome | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Naltrexone / Bupropion (Contrave) | Approved | Small molecule | Opioid receptor / dopamine (combination) | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| Orlistat (Xenical / Alli) | Approved | Small molecule | Pancreatic/gastric lipase | ||
| Phentermine / Topiramate (Qsymia) | Approved | Small molecule | Noradrenergic/anticonvulsant (combination) | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| Setmelanotide (Imcivree) | Approved | Peptide | MC4R | ||
| Tirzepatide (Zepbound / Mounjaro) | Approved | Peptide | GLP-1/GIP receptor (dual) | ||
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| Apitegromab | Phase 3 | Monoclonal antibody | Activin/myostatin type II receptor |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.